Does Blue Cross Blue Shield of North Carolina Cover Wegovy?
The verdict
Conditional on most plans
Blue Cross Blue Shield of North Carolina's Wegovy coverage has been significantly cut in two areas: the NC State Health Plan (the large public-employee plan) dropped weight-loss GLP-1 coverage in 2024, and NC Medicaid removed obesity coverage effective October 1, 2025. Private commercial coverage varies by employer. The cardiovascular, MASH, and sleep-apnea indications remain covered where applicable even where obesity coverage was removed.
Coverage is set by your specific plan and formulary. This is a research summary — always confirm with Blue Cross Blue Shield of North Carolina using your member ID.
Key facts
North Carolina Medicaid removed GLP-1 obesity coverage effective October 1, 2025 — retaining coverage for the cardiovascular, MASH, and OSA indications.
NC DHHS / NC Medicaid preferred drug list update, 2025
The NC State Health Plan, covering public employees and teachers, dropped weight-loss GLP-1 coverage in 2024 due to projected cost growth.
NC State Health Plan communications, 2024
The Medicare GLP-1 Bridge launches July 1, 2026, giving eligible Medicare beneficiaries Wegovy weight-loss access at $50/month outside Part D — not counting toward the $2,100 OOP cap.
CMS.gov, Medicare GLP-1 Weight Loss Drug Access Program
Medicare vs. commercial coverage
Whether Blue Cross Blue Shield of North Carolina covers Wegovy depends heavily on which kind of plan you hold. They follow completely different rules — here's each one, side by side.
Medicare
Part D & Advantage plans
Medicare Part D cannot cover Wegovy for weight loss by statute — this applies to all BCBS-NC Medicare plans. BCBS-NC Medicare Advantage plans can cover Wegovy for the cardiovascular risk-reduction indication (FDA-approved for adults with established CVD who are overweight or obese) with prior authorization. The Medicare GLP-1 Bridge launches July 1, 2026, giving eligible Medicare beneficiaries weight-loss access to Wegovy at $50/month through December 31, 2027 — this operates outside Part D, so the $50 does not count toward the $2,100 OOP cap or TrOOP. Extra Help cannot be applied to Bridge copays. NovoCare savings card is not available to Medicare beneficiaries.
Commercial / Employer
Group & marketplace plans
BCBS-NC commercial and employer plan coverage varies by employer group. For the NC State Health Plan — which covers North Carolina public employees, teachers, and retirees — weight-loss GLP-1 coverage was dropped in 2024, citing cost. For other commercial employer plans, coverage is employer-dependent: weight-loss Wegovy is covered only where the employer purchased the anti-obesity benefit. Per-plan drug tier and cost-share are not publicly published at the drug level; verify via BCBS-NC's drug-lookup tool. ACA/individual-market plans generally exclude Wegovy for weight loss. NC Medicaid removed obesity GLP-1 coverage effective October 1, 2025 — the CV indication (for members with established CVD), MASH (moderate-to-advanced fibrosis), and OSA indications remain covered under NC Medicaid where the qualifying diagnosis is documented. NovoCare savings card ($25/month, max $100/28-day supply) is available to commercially insured members whose plan covers Wegovy; not available to Medicaid or Medicare beneficiaries.
The 5 boxes you must tick to get approved
Commercial plans that will consider Wegovy require prior authorization. Check off what applies to you to see how close you are — this is a guide, not a guarantee of approval.
Meet all 5 and you have a documented case for approval. Missing any one is the most common reason requests are denied.
Your cost, three ways
What Wegovy actually costs you swings enormously depending on how it's covered. Here's the realistic range.
Paying cash
$1,349/month (Novo Nordisk published list price for a 28-day supply). NovoCare self-pay: approximately $349/month for standard injection doses after an introductory period through December 31, 2026.
List price with no coverage — before any manufacturer savings card.
With coverage
Plan-specific cost-share where covered — not publicly published at the drug level. Confirm your specific cost-share on BCBS-NC's drug-lookup tool or member portal. NovoCare savings card: commercially insured members whose plan covers Wegovy may pay as little as $25/month (max $100 per 28-day supply). Not available to Medicare or Medicaid beneficiaries.
Typical monthly copay once prior authorization is approved.
Bridge program
Medicare GLP-1 Bridge: $50/month fixed copay for eligible Medicare beneficiaries, launching July 1, 2026, through December 31, 2027. Operates outside Part D — does not count toward the $2,100 OOP cap, TrOOP, or Extra Help. Provider must attest eligibility at initiation.
Reduced copay through the assistance program, where eligible.
All cost figures are estimates. Actual cost-share varies by plan tier, deductible phase, and pharmacy — confirm with your BCBS-NC plan and pharmacist before starting treatment.
Check YOUR exact coverage in 3 steps
General answers only get you so far. Here's how to confirm your own plan's decision in a few minutes.
- 1
Identify your specific plan: NC State Health Plan, private employer, or Medicaid
The NC State Health Plan (public employees/teachers/retirees) dropped weight-loss GLP-1 coverage in 2024. NC Medicaid removed obesity coverage October 1, 2025. Private employer plans vary. Knowing which plan you're on determines your starting point before any formulary search.
- 2
Search BCBS-NC's drug-lookup tool for your specific plan
Go to bcbsnc.com and use the formulary or drug-lookup tool with your member ID. Search for 'Wegovy' or 'semaglutide 2.4 mg' to confirm whether your specific plan includes the anti-obesity benefit and what the PA requirements are.
- 3
Ask your prescriber about retained medical indications
If you have established cardiovascular disease, MASH with moderate-to-advanced fibrosis, or obstructive sleep apnea, Wegovy may be coverable under those indications even where obesity coverage was removed. Discuss with your prescriber whether you qualify, as these are separate FDA-approved pathways distinct from weight management.
Options if Blue Cross Blue Shield of North Carolina won't cover Wegovy
A denial isn't the end of the road. These are the paths people commonly explore next — discuss any of them with your prescriber.
Cardiovascular, MASH, and OSA indications
NC Medicaid retained coverage for Wegovy's cardiovascular risk-reduction (established CVD), MASH (moderate-to-advanced fibrosis), and sleep-apnea indications even after removing obesity coverage on October 1, 2025. If you have one of these qualifying diagnoses, discuss with your prescriber whether a PA under the retained indication is appropriate.
NovoCare self-pay program
Novo Nordisk's NovoCare Pharmacy offers Wegovy at approximately $349/month for patients without coverage. An introductory rate of approximately $199/month applies to the 0.25 and 0.5 mg doses through December 31, 2026. List price is announced to drop to approximately $675/month effective January 1, 2027.
Compounded semaglutide
Compounded semaglutide is available without insurance for patients who cannot access covered Wegovy. See the Curex offer below. Compounded medications are not the same as Wegovy and have not been approved by the FDA.
These options are listed for information only — your own clinician decides what is appropriate for you.
❓Frequently Asked Questions
BCBS-NC commercial coverage varies by employer. However, two significant pullbacks define the NC landscape: the NC State Health Plan dropped weight-loss GLP-1 coverage in 2024, and NC Medicaid removed obesity coverage effective October 1, 2025. Private employer plans are employer-dependent — verify via BCBS-NC's drug-lookup tool at bcbsnc.com. The cardiovascular, MASH, and OSA indications remain covered even where obesity coverage was removed. ACA/individual plans generally exclude weight-loss GLP-1s.
North Carolina made two coverage pullbacks driven by cost. The NC State Health Plan dropped weight-loss GLP-1 coverage in 2024 after projecting major cost increases from broad GLP-1 obesity use. NC Medicaid followed, removing obesity coverage effective October 1, 2025, while retaining coverage for the cardiovascular, MASH, and OSA indications. These pullbacks are consistent with a national trend of public-payer programs reducing discretionary anti-obesity drug spending while preserving coverage for medical necessity indications.
NC Medicaid removed obesity GLP-1 coverage effective October 1, 2025, but retained coverage for Wegovy's cardiovascular risk-reduction indication (for adults with established CVD who are overweight or obese), MASH with moderate-to-advanced fibrosis (an FDA indication added August 2025), and obstructive sleep apnea. These are distinct from weight management. If you have one of these qualifying diagnoses, your prescriber can submit a PA under the retained indication — Wegovy is not categorically excluded from NC Medicaid.
No. Medicare Part D cannot cover Wegovy for weight loss by statute — this applies to all BCBS-NC Medicare Advantage plans. BCBS-NC Medicare Advantage plans can cover Wegovy for the cardiovascular risk-reduction indication in members with established CVD with PA. The Medicare GLP-1 Bridge (launching July 1, 2026) provides weight-loss access at $50/month outside Part D for eligible beneficiaries — verify Bridge eligibility with your prescriber.
Both BCBS-NC and BCBS-Michigan made notable weight-loss GLP-1 coverage pullbacks in the 2024-2025 period, but they affected different lines of business. BCBS-Michigan ended weight-loss GLP-1 coverage on fully insured large-group commercial plans effective January 1, 2025. BCBS-NC's cuts came through the NC State Health Plan (public employees, 2024) and NC Medicaid (obesity removed October 1, 2025). Both retained non-obesity medical indications. The key difference: BCBS-MI's cut was employer-plan-facing, while BCBS-NC's most significant cuts were in the public-sector and Medicaid lines.
Related Articles
Does BCBS of Arizona Cover Wegovy? 2026 Guide | Curex
BCBS of Arizona covers Wegovy only where your employer opted in; formulary not published. Verify via drug-lookup and confirm with HR first.
Read moreDoes Blue Cross Blue Shield of Illinois Cover Wegovy? | Curex
BCBS Illinois (HCSC) covers Wegovy only where your employer opts in. ACA plans exclude it. Formulary not public — verify on your plan's drug-lookup tool.
Read moreDoes Blue Cross Blue Shield of North Carolina Cover Ozempic? 2026 | Curex
BCBS NC covers Ozempic for type 2 diabetes with prior auth — not weight loss. NC Medicaid kept T2D coverage while removing obesity GLP-1s in Oct 2025.
Read moreDoes BCBS Alabama Cover Wegovy? 2026 Guide | Curex
BCBS Alabama Wegovy coverage is employer-dependent and unpublished. Alabama Medicaid excludes obesity GLP-1s. How to verify your specific plan.
Read moreDoes BCBS Michigan Cover Wegovy? 2026 Coverage Guide | Curex
BCBS Michigan ended weight-loss GLP-1 coverage on fully insured plans in 2025. Self-funded groups may opt in. Michigan Medicaid covers Wegovy as preferred.
Read moreDoes BCBS of North Carolina Cover Mounjaro? 2026 | Curex
BCBS NC covers Mounjaro for type 2 diabetes with prior auth — not weight loss. The NC Medicaid weight-loss GLP-1 churn never affected Mounjaro.
Read moreWhether or not Blue Cross Blue Shield of North Carolina covers Wegovy, there's a path that skips insurance
North Carolina's state health plan and Medicaid both dropped weight-loss GLP-1 coverage. For patients facing those cuts, Curex offers compounded semaglutide from $49/mo (compounded tirzepatide from $149/mo) at getcurex.com/cl/glp — no insurance, no prior authorization. Compounded semaglutide is not the same medication as Wegovy. Prescription required, subject to provider review.
- Medication + free shipping
- 24/7 provider access
- Medical intake & prescription review
Compounded semaglutide and tirzepatide are not the same medications as Wegovy and are not branded or FDA-approved products. Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.
This content is for informational purposes only and does not constitute medical, financial, or insurance advice. Coverage rules, prior-authorization criteria, and copay amounts change frequently and vary by plan, formulary tier, and effective date — always verify current benefits directly with Blue Cross Blue Shield of North Carolina before making any decision. Consult a licensed healthcare provider and your plan administrator for guidance specific to your situation. Curex offers compounded semaglutide and tirzepatide, which are not the same medications as Wegovy and are not branded or FDA-approved products; prescription required, subject to provider review. Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.